Collaborators LoginAuthor: dev_team
Cerveau Technologies, Inc. Announces Initiation of Japanese Phase I Study
Cerveau Technologies, Inc. Announces a Partnership with LuMind IDSC Foundation to Study Accumulation of Neurofibrillary Tau in Down Syndrome
Cerveau Technologies Inc. Signs Research Agreement with Eisai Inc., for Novel Tau Imaging Agent
Cerveau Technologies, Inc. and Institut de Radiofarmacia Aplicada de Barcelona, S.L. Announce Agreement to Manufacture Investigational Tau Ligand
Cerveau Technologies, Inc. to Support a First Clinical Study in Asia of a Novel Biomarker of Alzheimer’s Disease
Cerveau Technologies Inc. Signs Research Agreement with Ionis Pharmaceuticals, Inc. for Novel Tau Imaging Agent
Cerveau Technologies Inc. Announces Expanded Research Access to Novel Tau Imaging Agent
Cerveau Technologies, Inc. Signs Research Agreement with Tokyo Metropolitan Institute of Gerontology, Japan
Cerveau Technologies, Inc. Signs Research Agreement with Massachusetts General Hospital
Cerveau Technologies, Inc. Signs Research Agreement with University of Pittsburgh
Cerveau Technologies, Inc. Signs Research Agreement with KU Leuven University, Belgium
Cerveau Technologies, Inc. Signs Research Agreement with VU Medical Center Amsterdam
Cerveau Technologies, Inc. and Enigma Biomedical Group, Inc., Sign Research Agreement with Centre for Addiction and Mental Health (CAMH), Toronto
Cerveau Technologies, Inc. Signs Research Agreement with Houston Methodist
Cerveau Technologies and Sinotau Pharmaceutical Group Announce Sinotau’s Achievement of a Major Milestone in China Strategy
Cerveau Technologies, Inc. Announces a Partnership with Landmark Alzheimer’s Disease DIAN-TU Trial
Cerveau Technologies Inc. Signs License and Supply Agreement with AbbVie for Novel Tau Imaging Agent
BOSTON–(BUSINESS WIRE)– Cerveau Technologies Inc. today announced a license and supply agreement with AbbVie for use of [F-18]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain.
Cerveau Technologies, Inc. Announces Collaboration with Banner Health
Cerveau Technologies Inc. Signs Collaboration Agreement with H. Lundbeck A/S for Novel Tau Imaging Agent
Imanova Secures License from Cerveau Technologies, Inc. to Manufacture Investigational Tau Ligand
Cerveau Technologies, Inc. Announces Collaboration with NYU Langone Medical Center
Cerveau Technologies, Inc. Announces FDA Acceptance of Investigational New Drug (IND) for Tau Imaging Agent MK-6240
Cerveau Technologies, Inc. Collaborates With Singapore’s Clinical Imaging Research Centre
Cerveau Technologies, Inc. Signs Clinical Supply Agreement with Merck for Investigational Tau Imaging Agent
Cerveau Technologies, Inc. Executes a Binding Term Sheet with Sinotau Pharmaceutical Group for Novel Investigational Tau Imaging Agent
Cerveau Tapped for Alzheimer’s Research
Cerveau has signed a research agreement through which it will supply its early-stage imaging agent to assess the stages of Alzheimer’s disease and other neurodegenerative diseases.